Diabetes prevalence and risk factors in polycystic ovary syndrome

Obstetrics and Gynecology Clinics of North America

Volumn 28, Issue 1, 2001, Pages 99-109

  Legro, R S ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANOVULATION; DIABETES MELLITUS; FAMILY HISTORY; GENETIC SCREENING; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIFESTYLE; OBESITY; OVARY POLYCYSTIC DISEASE; PANCREAS ISLET BETA CELL; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0035085864     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8545(05)70188-1     Document Type: Article

References (48)

1. Impact of family history of diabetes on the assessment of beta-cell function
2. Diabetes epidemiology: Collaborative analysis of diagnostic criteria in Europe
3. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone
4. Cardiovascular disease in older adults with glucose disorders: Comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria
5. Insulin sensitivity is not impaired in Mexican-American women without a family history of diabetes
6. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome?
7. Weight as a risk factor for clinical diabetes in women
8. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: A long-term follow-up focusing on natural history and circulating hormones
9. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease
10. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: Hormonal and metabolic profile
11. Beta-cell dysfunction on independent of obesity and glucose intolerance in the polycystic ovary syndrome
12. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia
13. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome
14. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome
15. Ethnicity and polycystic ovary syndrome are associated with independent and additive decreases in insulin action in Caribbean-Hispanic women
16. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome
17. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome
18. Insulin secretory defects in polycystic ovary syndrome: Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus
19. Hyperinsulinemia in the polycystic ovary syndrome - A clinical, endocrine, and echographic study in 240 patients
20. Beta-cell dysfunction in first-degree relatives of patients with non-insulin-dependent diabetes mellitus
21. Insulin action and age: European Group for the Study of Insulin Resistance (EGIR)
22. Polycystic ovary syndrome
23. 1 for impaired glucose tolerance in polycystic ovary syndrome
24. Exercise, glucose transport, and insulin sensitivity
25. Risk factors for non-insulin-dependent diabetes mellitus
26. Impaired glucose tolerance-prevalence and conversion to NIDDM
27. Comparison of diabetes diagnostic categories in the US population according to 1997 American Diabetes Association and 1980-1985 World Health Organization diagnostic criteria
28. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in US population aged 20-74 yr
29. Predicting future diabetes in Latino women with gestational diabetes: Utility of early postpartum glucose tolerance testing
30. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: A prospective study
31. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: A prospective, controlled study in 254 affected women
32. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: A randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation
33. Ethnic differences in insulin and glucose response to glucose between white and Indian women with polycystic ovary syndrome
34. Defects in beta-cell function in functional ovarian hyperandrogenism
35. Normal basal and insulin-stimulated fuel metabolism in lean women with the polycystic ovary syndrome
36. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: The Da Qing IGT and diabetes study
37. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome
38. Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM: Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative
39. The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries
40. A two-step model for development of non-insulin-dependent diabetes
41. The natural history of impaired glucose tolerance in the Pima Indians
42. Effects of metformin in obese patients with impaired glucose tolerance
43. Abnormal menstrual cycle length predicts subsequent diabetes mellitus
44. Features of syndrome X in first-degree relatives of NIDDM patients
45. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: Results of a case-control study
46. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: The Funagata diabetes study
47. Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM
48. Obesity, lipids, cardiovascular risk, and androgen excess